Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf HoldingsCURLF -7.33%73 Intrinsic Value: Projected FCF is $0.99 as of Aug. 05, 2026, which is 93% below its 10-year median of 13.88. GuruFocus rates CURLF with a GF Score™ of 73/100 and a GF Value™ of $8.05 (Fairly Valued). The stock has 5 warning signs investors should review. Among 634 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 92.74% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-05), Curaleaf Holdings's Intrinsic Value: Projected FCF is $0.99. The stock price of Curaleaf Holdings is $8.35. Therefore, Curaleaf Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 8.4.
The historical rank and industry rank for Curaleaf Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:
CURLF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 6.47 Med: 13.88 Max: 409
Current: 8.43
During the past 12 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Curaleaf Holdings was 409.00. The lowest was 6.47. And the median was 13.88.
CURLF's Price-to-Projected-FCF is ranked worse than 92.74% of 634
companies
in the Drug Manufacturers industry
Industry Median: 1.535
vs CURLF: 8.43
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Curaleaf Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
8.35
/
0.90429042129624
=
9.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings Intrinsic Value: Projected FCF Related Terms
Curaleaf Holdings Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CURLF vs ZTS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.99 mean?
Curaleaf Holdings (CURLF) has a Intrinsic Value: Projected FCF of $0.99 as of Aug. 05, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Curaleaf Holdings and its competitors. This is 93% below median its historical median of 13.88. Over the past decade, Curaleaf Holdings' Intrinsic Value: Projected FCF has ranged from 6.47 to 409.00. According to the industry distribution chart, Curaleaf Holdings ranks #588 out of 634 companies in the Drug Manufacturers industry, placing it in the top 92.7%.
Is Curaleaf Holdings' Intrinsic Value: Projected FCF too high?
Curaleaf Holdings' current Intrinsic Value: Projected FCF of $0.99 is 93% below median its 10-year median of 13.88. Over the past 10 years, this metric has ranged from a low of 6.47 to a high of 409.00. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.54. Curaleaf Holdings' value of $0.99 is 35.5% below this industry median. Based on the distribution chart, Curaleaf Holdings ranks #588 out of 634 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curaleaf Holdings has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Intrinsic Value: Projected FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #588 out of 634 companies for Intrinsic Value: Projected FCF. This places Curaleaf Holdings in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.54. Curaleaf Holdings' value of $0.99 is 35.5% below this benchmark. Historically, Curaleaf Holdings' own Intrinsic Value: Projected FCF has ranged from 6.47 to 409.00 over the past decade. While the company's 10-year median is 13.88 vs. the industry median of 1.54, Curaleaf Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.54, based on 634 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Intrinsic Value: Projected FCF of $0.99 is 35.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Intrinsic Value: Projected FCF is $0.99, which is 93% below median its own 10-year median of 13.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Fairly Valued. The stock's GF Value™ is $8.05, compared to a current price of $8.35 — trading 3.7% above its estimated fair value. The current Intrinsic Value: Projected FCF is $0.99, which is 93% below median its 10-year median of 13.88 and 35.5% below the Drug Manufacturers industry median of 1.54. Curaleaf Holdings' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Intrinsic Value: Projected FCF is $0.99 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $8.35 is trading 3.7% above its estimated GF Value™ of $8.05.
GuruFocus considers Curaleaf Holdings to be Fairly Valued.
Key valuation signals for CURLF:
Intrinsic Value: Projected FCF: $0.99 (93% below median its 10-year median of 13.88)
GF Value™: $8.05 vs. price of $8.35 (3.7% above fair value)
Industry Position: 35.5% below the Drug Manufacturers median (#588 of 634)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
73GF Score
Get the complete analysis for CURLF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
